AZD0156: Precision ATM Kinase Inhibition for DNA Damage Response

Executive Summary: AZD0156 is an orally bioavailable, small-molecule inhibitor targeting ataxia telangiectasia mutated (ATM) kinase, with sub-nanomolar potency and >1,000-fold selectivity over related PIKK family enzymes (product information). ATM kinase orchestrates the cellular response to DNA double-strand breaks, ensuring genomic stability and regulating checkpoint control (Huang et al., 2023). Inhibition of ATM by AZD0156 not only sensitizes tumor cells to DNA-damaging agents but also induces metabolic adaptation via macropinocytosis, revealing new therapeutic vulnerabilities. APExBIO provides AZD0156 (SKU B7822) at ≥98% purity, with detailed solubility and storage specifications for research use. This article synthesizes recent peer-reviewed evidence, product benchmarks, and practical workflow guidance, updating and extending previous reviews on selective ATM inhibition.

Biological Rationale

ATM kinase is a central regulator of the DNA damage response (DDR), particularly upon detection of DNA double-strand breaks. Upon activation, ATM phosphorylates multiple substrates, leading to cell cycle checkpoint activation, DNA repair, and maintenance of genomic integrity (Huang et al., 2023). Loss or inhibition of ATM function results in impaired checkpoint control and increased genomic instability, which are key drivers in cancer pathogenesis. Recent studies have also revealed ATM's role in cellular metabolism and nutrient uptake, adding a new dimension to its established functions (Huang et al., 2023).

Mechanism of Action of AZD0156

AZD0156 is a potent, selective inhibitor of ATM kinase, a serine/threonine kinase in the PIKK family. It binds competitively to the ATP-binding site of ATM, blocking its kinase activity and preventing phosphorylation of downstream effectors involved in DNA repair and checkpoint regulation (APExBIO product page). AZD0156 demonstrates sub-nanomolar inhibition of cellular ATM signaling and shows >1,000-fold selectivity over other PIKK enzymes, including ATR, DNA-PK, and mTOR. This specificity ensures minimal off-target effects, making AZD0156 a valuable tool for dissecting ATM-dependent pathways (related article).

Evidence & Benchmarks

• AZD0156 exhibits sub-nanomolar inhibitory potency against ATM kinase activity in cellular assays (product information).
• Selective inhibition of ATM by AZD0156 (>1,000-fold over other PIKK family kinases) is confirmed by enzymatic and cellular profiling (product information).
• In preclinical cancer models, oral AZD0156 (administered at defined doses) enhances the antitumor response to DNA double-strand break-inducing agents such as ionizing radiation and topoisomerase inhibitors (overview article).
• ATM inhibition by AZD0156 induces metabolic adaptation in cancer cells, notably increasing macropinocytosis and nutrient scavenging under nutrient-poor conditions (Huang et al., 2023).
• Combined inhibition of ATM and macropinocytosis leads to suppression of tumor cell proliferation and induction of cell death both in vitro and in vivo (Huang et al., 2023).
• AZD0156 is supplied as a solid with a molecular weight of 461.56, chemical formula C₂₆H₃₁N₅O₃, and is soluble at ≥23.1 mg/mL in DMSO, ≥5.49 mg/mL in ethanol, but insoluble in water (product information).
• Long-term storage of AZD0156 solutions is not recommended; solid should be stored at -20°C for optimal stability (product information).

Compared to previous reviews which focused on biochemical rationale and best practices, this article synthesizes recent metabolic findings and clinical translation data.

Applications, Limits & Misconceptions

AZD0156 is primarily used in oncology research to potentiate the effects of DNA-damaging agents and to dissect the role of ATM in DNA damage response and metabolic adaptation. Its high specificity allows for precise modulation of checkpoint control in cellular and animal models. Early clinical trials are investigating its safety and efficacy in advanced cancers. AZD0156 also serves as a reference compound to probe ATM-dependent metabolic pathways, including macropinocytosis and amino acid uptake (Huang et al., 2023).

Common Pitfalls or Misconceptions

• AZD0156 is not effective in water-based formulations due to its insolubility in water; DMSO or ethanol are required for solution preparation (product info).
• Long-term storage of AZD0156 solutions at room temperature or 4°C leads to degradation; always store the solid at -20°C (specification).
• AZD0156 is not a pan-PIKK inhibitor; its selectivity profile does not support use as an ATR, DNA-PK, or mTOR inhibitor (product info).
• The metabolic reprogramming effects observed with ATM inhibition are context-dependent and may vary with tumor type and p53/c-MYC status (Huang et al., 2023).
• Use in humans is currently investigational and limited to clinical trial settings; not approved for routine clinical therapy (APExBIO).

For a detailed comparison with checkpoint modulation and clinical synergy, see 'AZD0156: Precision ATM Kinase Inhibition for Cancer Thera...'—this article extends that review with metabolic adaptation insights from recent peer-reviewed research.

For further mechanistic benchmarks and best practices, 'AZD0156: Selective ATM Kinase Inhibitor for Cancer Research' details workflow integration, while this article emphasizes metabolic impact and clinical transition.

Workflow Integration & Parameters

Protocol Parameters

• Compound dissolution: Dissolve AZD0156 at ≥23.1 mg/mL in DMSO with gentle warming; for ethanol, use ≥5.49 mg/mL (product info).
• Storage: Store solid AZD0156 at -20°C; avoid repeated freeze-thaw cycles. Prepare fresh solutions before use; long-term storage of solutions is not recommended (product info).
• In vitro ATM inhibition: Use AZD0156 in cellular assays at concentrations validated for sub-nanomolar ATM inhibition; titrate according to cell line and endpoint (Huang et al., 2023).
• In vivo dosing: Oral administration protocols should reference published preclinical studies for dosing regimens and combination strategies with DNA-damaging agents (review).
• Checkpoint modulation: When modeling DDR, include appropriate controls for ATM-independent pathways to assess specificity (review).

Conclusion & Outlook

AZD0156, supplied with high purity by APExBIO, is a robust, selective ATM kinase inhibitor for dissecting DNA damage response and metabolic adaptation in cancer research. Peer-reviewed evidence demonstrates that ATM inhibition not only impairs double-strand break repair and checkpoint control but also induces metabolic vulnerabilities via macropinocytosis, suggesting new avenues for therapeutic intervention (Huang et al., 2023). Ongoing clinical trials will clarify its translational impact and optimal therapeutic combinations. Future research should further elucidate tumor-specific responses and metabolic context to optimize the utility of AZD0156 in precision oncology.